Tumor Suppressors Status in Cancer Cell Line Encyclopedia

被引:22
|
作者
Sonkin, Dmitriy [1 ]
Hassan, Mehedi [1 ]
Murphy, Denis J. [1 ]
Tatarinova, Tatiana V. [1 ,2 ]
机构
[1] Univ South Wales, Pontypridd CF37 1DL, M Glam, Wales
[2] Univ So Calif, Lab Appl Pharmacokinet, Los Angeles, CA 90089 USA
关键词
Tumor suppressor; Cancer cell line; CCLE; Loss of function; DNA methylation; Epigenetics; DATABASE; GENE; MDM2; MUTATION; PATHWAY; SAMPLES; TP53;
D O I
10.1016/j.molonc.2013.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor suppressors play a major role in the etiology of human cancer, and typically achieve a tumor-promoting effect upon complete functional inactivation. Bi-allelic inactivation of tumor suppressors may occur through genetic mechanisms (such as loss of function mutation, copy number (CN) loss, or loss of heterozygosity (LOH)), epigenetic mechanisms (such as promoter methylation or histone modification), or a combination of the two. We report systematically derived status of 69 known or putative tumor suppressors, across 799 samples of the Cancer Cell Line Encyclopedia. In order to generate such resource we constructed a novel comprehensive computational framework for the assessment of tumor suppressor functional "status". This approach utilizes several orthogonal genomic data types, including mutation data, copy number, LOH and expression. Through correlation with additional data types (compound sensitivity and gene set activity) we show that this integrative method provides a more accurate assessment of tumor suppressor status than can be inferred by expression, copy number, or mutation alone. This approach has the potential for a more realistic assessment of tumor suppressor genes for both basic and translational oncology research. (C) 2013 Federation. of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:791 / 798
页数:8
相关论文
共 50 条
  • [41] Prostaglandin catabolic enzymes as tumor suppressors
    Tai, Hsin-Hsiung
    CANCER AND METASTASIS REVIEWS, 2011, 30 (3-4) : 409 - 417
  • [42] Prostaglandin catabolic enzymes as tumor suppressors
    Hsin-Hsiung Tai
    Cancer and Metastasis Reviews, 2011, 30 : 409 - 417
  • [43] (de)MYSTification and INGenuity of tumor suppressors
    N. Saksouk
    N. Avvakumov
    J. Côté
    Cellular and Molecular Life Sciences, 2008, 65 : 1013 - 1018
  • [44] Heterogeneity of the cancer cell line metabolic landscape
    Shorthouse, David
    Bradley, Jenna
    Critchlow, Susan E.
    Bendtsen, Claus
    Hall, Benjamin A.
    MOLECULAR SYSTEMS BIOLOGY, 2022, 18 (11)
  • [45] CellLineNavigator: a workbench for cancer cell line analysis
    Krupp, Markus
    Itzel, Timo
    Maass, Thorsten
    Hildebrandt, Andreas
    Galle, Peter R.
    Teufel, Andreas
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D942 - D948
  • [46] Functional Mechanisms for Human Tumor Suppressors
    Sun, Wanpeng
    Yang, Jian
    JOURNAL OF CANCER, 2010, 1 : 136 - 140
  • [47] Tumor suppressors in acute myeloid leukemia
    Wallwitz, Jacqueline
    Aigner, Petra
    Stoiber, Dagmar
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2320 - 2330
  • [48] DUBs and cancer The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors
    Hussain, Sajjad
    Zhang, Ying
    Galardy, Paul J.
    CELL CYCLE, 2009, 8 (11) : 1688 - 1697
  • [49] Tumor Suppressors in Zebrafish: From TP53 to PTEN and Beyond
    den Hertog, Jeroen
    CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS, 2016, 916 : 87 - 101
  • [50] Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
    Leroy, Bernard
    Girard, Luc
    Hollestelle, Antoinette
    Minna, John D.
    Gazdar, Adi F.
    Soussi, Thierry
    HUMAN MUTATION, 2014, 35 (06) : 756 - 765